Search Results - "Ghayouri, Leila"

Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial by Nickols, Nicholas G, Goetz, Matthew B, Graber, Christopher J, Bhattacharya, Debika, Soo Hoo, Guy, Might, Matthew, Goldstein, David B, Wang, Xinchen, Ramoni, Rachel, Myrie, Kenute, Tran, Samantha, Ghayouri, Leila, Tsai, Sonny, Geelhoed, Michelle, Makarov, Danil, Becker, Daniel J, Tsay, Jun-Chieh, Diamond, Melissa, George, Asha, Al-Ajam, Mohammad, Belligund, Pooja, Montgomery, R. Bruce, Mostaghel, Elahe A, Sulpizio, Carlie, Mi, Zhibao, Dematt, Ellen, Tadalan, Joseph, Norman, Leslie E, Briones, Daniel, Clise, Christina E, Taylor, Zachary W, Huminik, Jeffrey R, Biswas, Kousick, Rettig, Matthew B

“…Background Therapeutic targeting of host-cell factors required for SARS-CoV-2 entry is an alternative strategy to ameliorate COVID-19 severity. SARS-CoV-2…”
Get full text

Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer by Nickols, Nicholas George, Tsai, Sonny, Kane, Nathanael, Diaz-Perez, Silvia, Ghayouri, Leila, Tran, Samantha, Duriseti, Sai, Valle, Luca, Lee, Steve Pai-hsun, Kwon, Robert, Gin, Greg E, Chang, Michael George, Chao, Hann-Hsiang, Steinberg, Michael L., Reiter, Robert Evan, Kishan, Amar Upadhyaya, Berenji, Gholam Reza, Aronson, William, Garraway, Isla, Rettig, Matthew

“…163 Background: Treatment paradigms for oligometastatic castration-sensitive prostate cancer patients are evolving. Molecular imaging improves staging,…”
Get full text

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer by Nickols, Nicholas G., Tsai, Sonny, Kane, Nathanael, Tran, Samantha, Ghayouri, Leila, Diaz-Perez, Silvia, Thein, May, Anderson-Berman, Nancy, Eason, Jeanie, Kishan, Amar U., Steinberg, Michael L., Reiter, Robert E., Lee, Steve P., Gin, Greg E., Kwon, Robert, Chang, Michael G., Chao, Hann-Hsiang, Solanki, Abhiskek A., Sexton, Rachael, Lewis, Michael, Lorentz, William, Cheung, Michael K., Gage, Diana L., Duriseti, Sai, Valle, Luca, Berenji, Gholam, Aronson, William J., Garraway, Isla P., Rettig, Matthew B.

Get full text

Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial by Nickols, Nicholas G, Mi, Zhibao, DeMatt, Ellen, Biswas, Kousick, Clise, Christina E, Huggins, John T, Maraka, Spyridoula, Ambrogini, Elena, Mirsaeidi, Mehdi S, Levin, Ellis R, Becker, Daniel J, Makarov, Danil V, Adorno Febles, Victor, Belligund, Pooja M, Al-Ajam, Mohammad, Muthiah, Muthiah P, Montgomery, Robert B, Robinson, Kyle W, Wong, Yu-Ning, Bedimo, Roger J, Villareal, Reina C, Aguayo, Samuel M, Schoen, Martin W, Goetz, Matthew B, Graber, Christopher J, Bhattacharya, Debika, Soo Hoo, Guy, Orshansky, Greg, Norman, Leslie E, Tran, Samantha, Ghayouri, Leila, Tsai, Sonny, Geelhoed, Michelle, Rettig, Mathew B

“…SARS-CoV-2 entry requires the TMPRSS2 cell surface protease. Antiandrogen therapies reduce expression of TMPRSS2. To determine if temporary androgen…”
Get full text